secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001104659-26-017118
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics receives Nasdaq minimum bid price deficiency notice; 180-day cure period
--------------------------------------------------------------------------------

- Received Nasdaq letter on Feb 18, 2026, for closing bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days, until August 17, 2026, to regain compliance.
- To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
- If not compliant by Aug 17, may be eligible for additional 180-day period if it meets other standards.
- Company will monitor bid price and evaluate options including reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926017118/0001104659-26-017118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926017118/tm266772d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-017118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer